Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,001 - 1,050 out of 11,034

Document Document Title
WO2005116002B1
The present invention relates to compounds with the formula (I), (II), (III) or (IV): (I) (II), (III), or (IV), wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the com...  
WO2005097114A3
The present invention relates to compounds of the Formula (I) wherein R1, R2, R3, R4, m, n and p are as defined. Compounds of the Formula (I) have activity inhibiting production of Aß-peptide. The invention also relates to pharmaceutica...  
WO/2006/086705A1
The present invention relates to a series of substituted bis aryl and heteroaryl compounds of formula (I): Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The compounds of this invention are selective 5HT2A antagonists, an...  
WO2005107762A3
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2006/085510A1
A remedy for IBS comprising, as the active ingredient, a dual antagonist for 5-HT2B and 5-HT7 receptors which shows selective binding affinities to 5-HT2B and 5-HT7 receptors. The above-described medicinal composition is superior in the ...  
WO/2006/083271A2
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...  
WO/2006/082597A2
The present invention discloses crystalline Polymorphic Form I of compound 5-(3,5- dimethylphenoxy-) methyl)-2-oxazolidinone, characterized by x-ray diffraction pattern having peaks at 10.355, 14.285,18.625, 19.030, 20.810 and 22.475± 0...  
WO/2006/083781A1
Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-p...  
WO2006044415A3
Peri-substituted, fused bicyclic ring carboxylic acids useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed.  
WO/2006/083924A1
1-Acylamino-2-hydroxy-3-amino-&ohgr -arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.  
WO/2006/082495A1
The present invention relates to novel acetic acid derivatives as peroxisome proliferator activated receptor (PPAR) modulators. Compounds described herein can be useful to inhibit or prevent diabetes or diabetes associated complications ...  
WO2005060456A8
The present invention relates to methods of treating ADAMTS-S-associated diseases and particularly osteoarthritis comprising administering an agent capable an of modulating ADMATS-5 activity to a subject afflicted with the disease. The a...  
WO/2006/080407A1
Disclosed is a PPAR&agr -selective activating compound which is pharmaceutically useful. Specifically disclosed is a benzoic acid derivative represented by the general formula (1) below, or a salt thereof. [In the formula, A represents a...  
WO/2006/077206A1
The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or -COO-C1-C4-alkyl group; Y represents NH, N-C1-C10-alkyl, O, or S; Z represents NH, N-C1-...  
WO2006066173A3
The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof usef...  
WO/2006/074797A1
Compounds of the formula (I): in which R1, R2, R3, R'3 and R4 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and dia­betes, the pharmaceutical compositions comprising them, and the...  
WO/2006/074501A1
The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in...  
WO/2006/074798A1
Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the...  
WO2005121130A3
This invention relates to compounds of the Formula (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-a or combinations...  
WO2006037775A8
Enantiopure heterocyclic compound Enantiopure heterocyclic compound of formula (I) in which J is chosen from C, N, O and S; Z is H or a group for protecting the amino functional group, R3 denotes H or an organic residue, m is 0, 1 or 2 a...  
WO/2006/074796A1
Compounds of the formula (1) in which R1, R2, X, Y and Z are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the ...  
WO/2006/075888A1
Provided are an oxazole hydroxamic acid derivative and a pharmaceutically useful salt thereof as a histone deacetylase inhibitor. The oxazole hydroxamic acid derivative and pharmaceutically useful salt thereof, prepared in accordance wit...  
WO2005070904A3
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at le...  
WO2005090302A3
The present invention provides a method for making substituted indole compounds of general formula III comprising the step of: (a) reacting a 2-bromoaniline or 2-chloroaniline of general formula (I); wherein: X, R and R1 are defined here...  
WO2006002088A3
Antitumor compounds based on the a1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells.  
WO2005112945A3
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among man...  
WO/2006/069811A2
Compounds of Formula (4) or (5) that absorb ultraviolet light 380 nm to 400 nm range but avoid absorption in the blue light range, thereby imparting yellowness, i.e., 410-420 nm: have suitable refractive characteristics useful in the pre...  
WO/2006/069656A1
The invention relates to compounds of the formula (I) in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as ...  
WO2005116002A3
The present invention relates to compounds with the formula (I), (II), (III) or (IV): (I) (II), (III), or (IV), wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the com...  
WO/2006/070878A1
It is intended to provide a compound which has an anticoagulant effect based on the inhibition of the activated blood coagulation factor VII and, therefore, is useful as a blood coagulation inhibitor or a preventive/remedy for diseases c...  
WO/2006/069685A1
The invention relates to compounds of formula (I), where A1, A2, R1, R2, R3, R4, R5 and Y have the meanings given in the description, methods and intermediates for production thereof and use thereof for the prevention of pests.  
WO/2006/069811A3
Compounds of Formula (4) or (5) that absorb ultraviolet light 380 nm to 400 nm range but avoid absorption in the blue light range, thereby imparting yellowness, i.e., 410-420 nm: have suitable refractive characteristics useful in the pre...  
WO/2006/067472A1
A compound of the formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; n is...  
WO/2006/069154A2
The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R’, RP, RP3, LP1, LP2, ZP, RB, RB’, LXB and ZXB are as hereinafter defined, their preparation, pharmaceut...  
WO/2006/066694A1
Disclosed is a method for producing oxazoles of formula IV by condensing aromatic aldehydes with a-ketoximes to N-oxides and then reacting the same with activated acid derivatives. The invention relates to a method for producing oxazoles...  
WO/2006/067086A1
The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or -COO-C1-C4-alkyl group; Y represents NH, N-C1-C10-alkyl, O, or S; Z represents NH, N-C1-...  
WO/2006/066173A2
The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof usef...  
WO/2006/063999A1
The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibi...  
WO/2006/066133A2
Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formula: wherein the variables are as defined herein.  
WO/2006/061376A1
The invention relates to a group of novel aryloxyethylamine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclose...  
WO/2006/061135A1
The present invention relates to compounds of the general formula (I) wherein R1 is the group (A) or (B) or (C) or (D); R2 is a non aromatic heterocycle, or is OR' or N(R')2; R' is lower alkyl, lower alkyl substituted by halogen or -(CH2...  
WO/2006/061377A1
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed...  
WO/2006/061193A1
The present invention relates to novel indenyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.  
WO/2006/061378A1
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed...  
WO/2006/059245A2
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, ...  
WO2006028972A3
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...  
WO2005107464A3
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.  
WO/2006/058905A1
The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula having the structural Formula (I), (II), (III) or (IV), stereoisomers, tautomers,...  
WO2005040139A8
The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated ...  
WO2006030211A3
Compounds of formula: (I) are found to antagonise N-type calcium channels wherein: - A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C3-C6 carbocycl...  

Matches 1,001 - 1,050 out of 11,034